Search

Your search keyword '"de Castro, J."' showing total 1,227 results
Start Over Author "de Castro, J." Language english
1,227 results on '"de Castro, J."'

1. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

Author

Zemanová, M., Besse, B., Bonnet, C., Cadranel, J., Chouaid, C., Cortot, A., Debieuvre, D., Delclaux, B., Denis, F., Duchemann, B., El Kouri, C., Ferrand, F.R., Ginoux, M., Hilgers, W., Madroszyk, A., Masson, P., Mazieres, J., Molinier, O., Moro-Sibilot, D., Pichon, E., Mascaux, C., Robinet, G., Roch, B., Zalcman, G., Schmidtke-Schrezenmeier, G., Schuette, W., Urban, L., Gottfried, M., Nechushtan, H., Peled, N., Wollner, M., Zer, A., Baldini, E., Bonanno, L., Bonetti, A., Cappuzzo, F., Delmonte, A., Galetta, D., Maio, M., Minotti, V., Rea, A., Romano, G., Tassinari, D., Tonini, G., Dziadziuszko, R., Karaszewska, B., Szczęsna, A., Cobo, M., De Castro, J., Felip, E., Garcia Campelo, M.R., Hernández, A., Moran, T., Provencio, M., Viteri, S., Dasgupta, A., Gabrail, N., Giaccone, G., Harshad, A., Liu, S., Oubre, D., Panikkar, R., Razaq, M., Sanborn, R., Garcia Campelo, R., Remon, J., Costantini, D., and Vasseur, B.

Published
2023
Full Text
View/download PDF

13. Cumulative Distribution Functions as Hysteresis Models.

Author

DE CAMPOS, M. F. and DE CASTRO, J. A.

Subjects
*CUMULATIVE distribution function, *DISTRIBUTION (Probability theory), *MAGNETIC noise, *SYMMETRIC functions, *GAUSSIAN function
Abstract

The cumulative distribution functions can be used as the basis for hysteresis models. Here it is de- scribed how, using only 3 parameters, including one representing the shape, hysteresis curves can be constructed using symmetric distribution functions. The model is useful in the interpretation of magnetic Barkhausen noise data. The model also has a clear physical meaning because it represents the distribution of coercivity inside the sample. An isotropic Stoner-Wohlfarth hysteresis was partially modelled by a three-parameter cumulative distribution function of Gaussian hysteresis for the 1st and 3rd quadrants. Asymmetric distributions will provide better hysteresis adjustment, but these are four- parameter models. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping

Author

Zugazagoitia, J., Ramos, I., Trigo, J.M., Palka, M., Gómez-Rueda, A., Jantus-Lewintre, E., Camps, C., Isla, D., Iranzo, P., Ponce-Aix, S., García-Campelo, R., Provencio, M., Franco, F., Bernabé, R., Juan-Vidal, O., Felip, E., de Castro, J., Sanchez-Torres, J.M., Faul, I., Lanman, R.B., Garrido, P., and Paz-Ares, L.

Published
2019
Full Text
View/download PDF

25. Nanotechnology boosts the production of clean energy via nanoparticle addition in anaerobic digestion.

Author

de Castro, J. Cunha, Resende, E., Taveira, Igor, Enrich-Prast, A., and Abreu, F.

Subjects
NANOTECHNOLOGY, CLEAN energy, ANAEROBIC digestion, BIOGAS production, METHANE
Abstract

Biogas production via anaerobic digestion is an established and robust technology that produces energy and recycles nutrients. Several biotechnological attempts have been applied to this process to increase biogas production, including adding nanoparticles, but several discrepancies have been reported. To elucidate the contradictory results, we performed a literature review followed by a meta-analysis to evaluate the effect of adding natural nanoparticles to biogas sludge. Our results showed that adding nanoparticles can increase biogas production by up to two orders of magnitude. Considering that, we attribute these results to variability in the nanoparticles applied, leading to less reliable, consistent, and even contradictory results. We observed that the magnetite nanoparticles are the most tested ones with the most promising positive effects. In addition, we observed that concentrations of nanoparticles higher than 100 mg/L can have adverse effects, with an overall decrease in biogas production. The findings in this study highlight the need for a proper characterization of the nanomaterials type and concentration applied to the process to understand the interactions and effects on the microbial communities and dynamics that lead to an overall increase or decrease in biogas yield. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer

Author

Isla D, De Castro J, Juan O, Grau S, Orofino J, Gordo R, Rubio-Terrés C, and Rubio-Rodríguez D

Subjects
adverse event, afatinib, cost-analysis, erlotinib, non-small-cell lung cancer., Medicine (General), R5-920, Therapeutics. Pharmacology, RM1-950
Abstract

Dolores Isla,1 Javier De Castro,2 Oscar Juan,3 Santiago Grau,4 Javier Orofino,5 Rocío Gordo,5 Carlos Rubio-Terrés,6 Darío Rubio-Rodríguez6 1Medical Oncology Department, Clinical Universitary Hospital Lozano Blesa, Zaragoza, 2Medical Oncology Department, Universitary Hospital La Paz, Madrid, 3Medical Oncology Department, Universitary and Polytechnic Hospital La Fe, Valencia, 4Pharmacy Department, Del Mar Hospital, Barcelona, 5Roche Farma, S.A., Health Economics, 6Health Value, Health Economics, Madrid, Spain Objectives: Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs) are an established treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutation. According to published meta-analyses, no significant efficacy differences have been demonstrated between erlotinib and afatinib. However, the incidence of EGFR–TKI-related adverse events (AEs) was lower with erlotinib. This study compares the cost of management of the AEs associated with these two drugs from the perspective of the Spanish National Health System (NHS).Methods: The frequency of AEs was established from a recently published meta-analysis. In Spain, the daily cost of both drugs can be considered similar; as a result, only the costs of management of the AEs were considered. Costs and resource utilization in the management of the AEs were estimated by a panel of Spanish oncologists and from studies previously carried out in Spain. A probabilistic analysis was performed based on a Monte Carlo simulation.Results: The model generated 1,000 simulations. The total cost per patient treated with erlotinib and afatinib was €657.44 and €1,272.15, respectively. With erlotinib, the cost per patient and per AE of grades ≤2 and ≥3 was €550.86 and €106.58, respectively, whereas the cost with afatinib was €980.63 and €291.52, respectively. The reduction in the number of AEs with erlotinib could avoid a mean cost for the NHS of €614.71 (95% CI: €342.57–881.29) per patient.Conclusion: In advanced EGFR mutation-positive NSCLC patients, first-line treatment with erlotinib could reduce health care costs for the NHS, due to a decrease in the AE rate compared with afatinib. In long-term treatments, the avoidance of complications and the lowering of costs associated with the management of AEs are relevant factors that contribute to the sustainability of the health system. Keywords: adverse event, afatinib, cost analysis, erlotinib, non-small cell lung cancer

Published
2016

36. A consensus statement on the gender perspective in lung cancer

Author

Isla, D., Majem, M., Viñolas, N., Artal, A., Blasco, A., Felip, E., Garrido, P., Remón, J., Baquedano, M., Borrás, J. M., Die Trill, M., García-Campelo, R., Juan, O., León, C., Lianes, P., López-Ríos, F., Molins, L., Planchuelo, M. Á., Cobo, M., Paz-Ares, L., Trigo, J. M., and de Castro, J.

Published
2017
Full Text
View/download PDF

37. Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy

Author

De Castro, J., González-Larriba, J. L., Vázquez, S., Massutí, B., Sanchez-Torres, J. M., Dómine, M., Garrido, P., Calles, A., Artal, A., Collado, R., García, R., Sereno, M., Majem, M., Macías, J. A., Juan, O., Gómez-Codina, J., Hernández, B., Lázaro, M., Ortega, A. L., Cobo, M., Trigo, J. M., Carcereny, E., Rolfo, C., Macia, S., Muñoz, J., Diz, P., Méndez, M., Rosillo, F., Paz-Ares, L., Cardona, J. V., and Isla, D.

Published
2017
Full Text
View/download PDF

38. EP.13A.05 Prognostic Laboratory Parameters in Imfirst: Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.

Author

de Castro, J., Cobo Dols, M., Dómine Gómez, M., Moreno Vega, A., Ponce Aix, S., Arriola, E., Carcereny, E., Majem, M., Huidobro Vence, G., Esteban González, E., Fuentes Pradera, J., Ortega Granados, A.L., Guillot Morales, M., Massuti Sureda, B., Fernández Núñez, N., Provencio, M., González-Mancha, N., Fajardo, C.A., Lerones, N., and García Campelo, R.

Published
2024
Full Text
View/download PDF

39. P1.13A.11 Patterns of Disease Progression after Atezolizumab Plus Chemotherapy in ES-SCLC: Exploratory Analysis from IMfirst Study.

Author

García-Campelo, R., Dómine Gómez, M., de Castro, J., Moreno Vega, A., Ponce Aix, S., Arriola, E., Carcereny, E., Majem, M., Huidobro Vence, G., Esteban González, E., Fuentes Pradera, J., Granados, A.L. Ortega, Guillot Morales, M., Massuti Sureda, B., Fernández Núñez, N., Provencio, M., González-Mancha, N., Fajardo, C.A., Lerones, N., and Cobo Dols, M.

Published
2024
Full Text
View/download PDF

40. P3.08E.04 TCR Metrics as Predictive Biomarkers of Response and Survival after Perioperative Chemoimmunotherapy. NADIM & NADIM II Trials

Author

Martínez-Toledo, C., Sierra, B., Molina-Alejandre, M., Casarrubios, M., Calvo, V., Nadal, E., García Campelo, M.R., Martínez-Martí, A., Garrido, A., Massutí, B., Insa, A., De Castro, J., Dómine, M., González-Larriba, J.L., Majem, M., Ponce, S., Barneto, I., Aguilar, A., Martín-López, J., Provencio, M., and Cruz- Bermúdez, A.

Published
2024
Full Text
View/download PDF

42. Neandertal roots: Cranial and chronological evidence from Sima de los Huesos

Author

Arsuaga, J. L., Martínez, I., Arnold, L. J., Aranburu, A., Gracia-Téllez, A., Sharp, W. D., Quam, R. M., Falguères, C., Pantoja-Pérez, A., Bischoff, J., Poza-Rey, E., Parés, J. M., Carretero, J. M., Demuro, M., Lorenzo, C., Sala, N., Martinón-Torres, M., García, N., de Velasco, A. Alcázar, Cuenca-Bescós, G., Gómez-Olivencia, A., Moreno, D., Pablos, A., Shen, C.-C., Rodríguez, L., Ortega, A. I., García, R., Bonmatí, A., de Castro, J. M. Bermúdez, and Carbonell, E.

Published
2014

45. Design of a Competitive and Collaborative Learning Strategy in a Communication Networks Course

Author

Regueras, L. M., Verdu, E., Verdu, M. J., and de Castro, J. P.

Abstract

In this paper, an educational methodology based on collaborative and competitive learning is proposed. The suggested approach has been successfully applied to an undergraduate communication networks course, which is part of the core curriculum of the three-year degree in telecommunications engineering at the University of Valladolid in Spain. This methodology is supported by two tools: the Moodle wiki for the collaborative part and a competitive learning tool called QUESTOURnament, which has been created by the authors to encourage the development of students' inquiry, documentation, and critical analysis skills while raising the level of involvement and communication between students and teachers. This paper describes how the collaborative and competitive approaches were combined and how the activities were ordered in phases. This educational proposal has been validated with academic outcomes and students' feedback. (Contains 6 tables and 2 figures.)

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results